CYTARABINE HYDROCHLORIDE

First approved in 1969

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13N3O5.ClH
Molecular Weight	279.678
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=KCURWTAZOZXKSJ-JBMRGDGGSA-N

InChI=1S/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H/t4-,6-,7+,8-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C9H13N3O5
Molecular Weight	243.2166
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA polymerase lambda 4 Target ID: CHEMBL5367 Sources: http://www.drugbank.ca/drugs/DB00987	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic myelogenous leukemia 22 Sources: https://clinicaltrials.gov/ct2/show/NCT00333840	Primary		Phase III 663	Unknown Approved Use Unknown
Lymphomatous meningitis 3 Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf	Primary		Approved 8360	CYTARABINE Approved Use Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia. Launch Date -1.71072E10

C_max

Value	Dose	Co-administered	Analyte	Population
62.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1900 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
40.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf	100 mg/m² 1 times / day multiple, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: DAUNORUBICIN	DAUNORUBICIN	CYTARABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
80 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/12162758	50 mg single, intrathecal dose: 50 mg route of administration: Intrathecal experiment type: SINGLE co-administered:		CYTARABINE unknown	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	Disc. AE: Cerebellar disorder NOS, Diarrhea... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 66.7%) Diarrhea (grade 3, 66.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS... AEs leading to discontinuation/dose reduction: Cerebellar disorder NOS (grade 4, 33.3%) Cerebellar disorder NOS (grade 5, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
3 g/m2 2 times / day multiple, intravenous MTD Dose: 3 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 3 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366	unhealthy, 16-76 n = 27 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 27 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366	Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.366
100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	Disc. AE: Bone marrow depression, Leukopenia... AEs leading to discontinuation/dose reduction: Bone marrow depression Leukopenia Thrombocytopenia Anemia Nausea Vomiting Diarrhea Abdominal pain Oral ulceration Hepatic dysfunction NOS Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Diarrhea	grade 3, 66.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
Cerebellar disorder NOS	grade 4, 66.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/6223674 Page: p.363, 366
Cerebellar disorder NOS	grade 4, 33.3% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
Cerebellar disorder NOS	grade 5, 16.7% Disc. AE	4.5 g/m2 2 times / day multiple, intravenous Highest studied dose Dose: 4.5 g/m2, 2 times / day Route: intravenous Route: multiple Dose: 4.5 g/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578	unhealthy, 16-76 n = 6 Health Status: unhealthy Condition: Acute leukemia Age Group: 16-76 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/7306918 Page: p.2578
Abdominal pain	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Anemia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Bone marrow depression	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Diarrhea	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Hepatic dysfunction NOS	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Leukopenia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Nausea	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Oral ulceration	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Thrombocytopenia	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1
Vomiting	Disc. AE	100 mg/m2 1 times / day multiple, intravenous Recommended Dose: 100 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Acute non-lymphocytic leukemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/15204103/ Page: 4.0	yes [IC50 6.6 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/15204103/ Page: 4.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:28680	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28680
MolPort	MolPort-001-792-509	https://www.molport.com/shop/molecule-link/MolPort-001-792-509
Selleck Chemicals	Cytarabine(Cytosar-U)	http://www.selleckchem.com/products/Cytarabine(Cytosar-U).html
ZINC	ZINC000003795098	http://zinc15.docking.org/substances/ZINC000003795098
eMolecules	1012736	https://www.emolecules.com/cgi-bin/more?vid=1012736

PubMed

Title	Date	PubMed
[Topotecan: a new field of use].	1999 Nov-Dec	10786197
Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia.	2000 Apr	10742073
Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.	2000 Jan-Feb	10772724
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.	2000 Jul	10914541
Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.	2000 Jul 1	10891466
Visual loss following high-dose cytosine arabinoside (ARA-C).	2000 Mar	10997890
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.	2000 Mar	10803936
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.	2000 May	10815900
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.	2000 May 1	10813714
Cytosine arabinoside induced acute interstitial nephritis in a patient treated for refractory anemia with excess of blasts in transformation.	2000 Nov	11096300
Misdiagnosis of broad-complex tachycardia.	2000 Nov-Dec	11080328
Heterotopia in microcephaly induced by cytosine arabinoside: hippocampus in the neocortex.	2000 Oct	10985699
Cerebellar toxicity of cytosine arabinoside: clinical and neuropsychological signs.	2000 Oct 24	11071510
Treatment for primary CNS lymphoma: the next step.	2000 Sep	10963643
Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp.	2001 Apr	11260632
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.	2001 Apr	11248327
The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway.	2001 Apr 1	11284018
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.	2001 Apr 1	11264164
Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells.	2001 Apr 15	11286995
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.	2001 Feb	11253603
Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.	2001 Feb	11232951
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.	2001 Feb	11216706
Bilateral breast relapse in acute myelogenous leukemia.	2001 Feb	11216705
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].	2001 Feb	11181327
Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia.	2001 Feb	11167822
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.	2001 Feb 15	11233917
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.	2001 Feb 15	11181656
Topoisomerase II inhibitor induced leukemia in a patient with AIDS.	2001 Feb 16	11273227
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP.	2001 Feb 2	11161392
Aseptic meningitis in a child after systemic treatment with high dose cytarabine.	2001 Jan	11176579
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.	2001 Jan	11167792
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.	2001 Jan	11161370
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.	2001 Jan	11146581
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy.	2001 Jan	11137558
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.	2001 Jan 1	11196156
Bcl-X(L)-caspase-9 interactions in the developing nervous system: evidence for multiple death pathways.	2001 Jan 1	11150333
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment.	2001 Jan 1	11148569
Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.	2001 Jan 10	11121862
JP-8 jet fuel-induced DNA damage in H4IIE rat hepatoma cells.	2001 Jan 25	11152973
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.	2001 Jan 3	11136838
Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons.	2001 Jan 31	11165379
Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.	2001 Jan 5	11139330
The CAG regimen (low-dose cytarabine, aclarubicin hydrochloride and granulocyte colony-stimulating factor) for the treatment of elderly acute myelomonocytic leukaemia: a case study.	2001 Jan-Feb	11277347
Therapy of acute myeloid leukemia.	2001 Jan-Feb	11176038
[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].	2001 Mar	11265415
Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.	2001 Mar	11241435
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.	2001 Mar	11237060
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.	2001 Mar	11237056
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.	2001 Mar	11226516
Severe hepatic injury associated with lipid formulations of amphotericin B.	2001 Mar 1	11229863

Patents

Sample Use Guides

In Vivo Use Guide

Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).

Route of Administration: Intratracheal

In Vitro Use Guide

Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:44:16 UTC 2023` Edited by `admin` on `Wed Jul 05 22:44:16 UTC 2023`
Record UNII	33K3DB6591
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CYTARABINE HYDROCHLORIDE

Official Name

English

2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-, MONOHYDROCHLORIDE

Common Name

English

U-19920A

Code

English

Cytarabine hydrochloride [WHO-DD]

Common Name

English

CYTARABINE HYDROCHLORIDE [USAN]

Common Name

English

1-.BETA.-D-ARABINOFURANOSYLCYTOSINE MONOHYDROCHLORIDE

Common Name

English

CYTARABINE HCL

Common Name

English

CYTOSINE ARABINOSIDE HYDROCHLORIDE

Common Name

English

NSC-63878

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1557